‘Abeta catabolism’ – special series call for submissions

- 0 Comments

Alzheimer’s Research & Therapy is now accepting research submissions for consideration in a special series on abeta catabolism, planned for publication in late 2013.

The publication of these articles will be co-ordinated with a series of commissioned reviews and opinions, guest edited by Dr Elizabeth Eckman (Atlantic Health) and written by leaders in the field including Gary Landreth (Case Western Reserve), Kristin Wildsmith (Genentech), Malcolm Leissring (Mayo clinic), Anthony Turner (Leeds) and Salvatore Oddo (UT Health Science Centre).

Submit your paper to this series and receive a 50% article processing charge discount – simply quote ‘AlzRTabeta’ at submission.

We welcome research manuscripts to accompany a series of articles reviewing the evidence for decreased Abeta clearance in Alzheimer’s disease (AD), describing the proteases known to degrade the peptide, and addressing how familial AD mutations and late-onset AD risk factors may act, at least in part, by altering Abeta clearance.

Novel therapies aimed at increasing Abeta clearance have already been shown to be effective in mouse models, and new therapeutic targets will undoubtedly emerge as the full range of clearance mechanisms in the brain is fully characterized.

The deadline for submissions is 31st July 2013. Please submit online and indicate in your covering letter that you would like the article to be considered for the abeta catabolism series.

Benefits of publishing in Alzheimer’s Research & Therapy include:

• International and rapid peer–review (first decision provided within 6 weeks)
• Prestigious Editorial Board
• Receiving first Impact Factor in June 2013
• Immediate publication on acceptance, no color figure charges or space limits and guaranteed unlimited global visibility for your research that open access publishing provides
• Inclusion in PubMed and PubMed Central and indexed in Web of Science database/Science citation index Expanded (SciSearch)

If you would like to enquire about the suitability of a study for consideration, please email editorial@alzres.com.

For further information about the journal, please visit the website, or contact us for enquires about the special series.